StockVS

Avalon GloboCare Corp. (ALBT) Aandelenanalyse

Vastgoed

Avalon GloboCare Corp.

$0.36

$-0.02 (-6.37%)

Laatst bijgewerkt: 26 mei 2026

Koersverloop

Analyse

Bedrijfsoverzicht

Avalon GloboCare Corp. is a specialized entity that owns and operates commercial real estate properties within the United States while simultaneously distributing the KetoAir breathalyzer system for acetone detection and AI Nutritionist software. The company operates within the Real Estate sector, specifically classified under the Real Estate Services industry, which suggests a focus on service-oriented property management or specialized distribution rather than pure development or investment. The firm maintains a market capitalization of $3.67M and reports annual revenue of $392,677 over the trailing twelve months, supported by a workforce of 2 employees. These valuation and revenue figures indicate a micro-cap status with extremely limited operational scale, where the disparity between the high price-to-sales ratio and the small absolute revenue suggests that the market is pricing in significant expectations regarding the non-real estate assets or specific software technologies, despite the nominal revenue stream being derived largely from property operations.

Financiële gezondheid

The financial performance of Avalon GloboCare Corp. over the trailing twelve months shows revenue of $392,677 paired with a net income of $-17,356,400 and an EBITDA of $-7,496,916, revealing a profound disconnect between top-line generation and bottom-line profitability. The massive negative gap between the modest revenue figure and the substantial net loss indicates an aggressive cost structure or significant non-operating expenses that consume nearly 44 times the total revenue generated. Free cash flow stands at $-1,903,116, which demonstrates that the company is consuming cash reserves rather than generating liquidity, thereby limiting its financial flexibility for capital expenditures or debt servicing. The company holds $109,091 in cash but carries $940,359 in debt, resulting in a debt-to-equity ratio of 10.19 that characterizes the balance sheet as highly leveraged and reliant on external financing. Operating margin is reported at -1933.2% and gross margin at 100.0%, while profit margin sits at 0.0%; this combination implies that while revenue recognition may be fully recognized before certain cost allocations, the operational overheads and interest expenses are so severe that they drive operating profits deeply negative. The current ratio of 0.11 indicates a severe liquidity constraint, as current liabilities exceed current assets by a significant margin, suggesting an inability to meet short-term obligations without refinancing. Return on Equity is -212.5% and return on assets is -21.4%, metrics that reveal management is currently destroying shareholder value and failing to generate returns on the capital base deployed in real estate and technology assets.

Waarderingsbeoordeling

The company presents a trailing P/E ratio and forward P/E ratio as N/A due to the negative earnings, which implies that traditional earnings-based valuation models are inapplicable and that market expectations rely entirely on asset backing or future turnaround potential rather than current profitability. The price-to-book ratio stands at -0.12, indicating that the market capitalization is valued below the net book value of the assets, suggesting a deep discount or potential insolvency concerns rather than a market premium over book value. Alternative valuation metrics such as a price-to-sales ratio of 9.34 and an EV/EBITDA of -4.27 suggest that investors are pricing the stock based on revenue multiples despite the negative earnings, possibly due to the perceived value of the software distribution or specific property holdings. The 52-week high is $5.25 and the 52-week low is $0.42; based on the available data, the current trading price sits within a range that reflects extreme volatility, though the exact current price is not explicitly provided in the source facts, the proximity to the low suggests the stock may be trading near the bottom of its recent historical range. The beta value is 0.10, which indicates that the stock's price volatility is significantly lower than the broader market, behaving almost as a non-cyclical asset despite its high debt load and negative earnings profile.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical data available within the provided facts to determine if earnings are growing faster or slower than revenue, leaving the trajectory of growth entirely opaque. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all earnings—or in this case, losses—and reinvests capital into operations rather than distributing income to shareholders. Since the payout ratio is zero and there are no dividends, the company is not returning cash to investors but is instead focused on survival or asset restructuring given the negative free cash flow and high debt. The overall growth and income profile for Avalon GloboCare Corp. is characterized by a complete absence of historical growth data and a total lack of dividend income, presenting a high-risk scenario where capital preservation is the primary concern rather than income generation or expansion.

Vergelijking met sectorgenoten

Avalon GloboCare Corp. (ALBT) is actief in de Vastgoeddiensten-sector. Zo verhoudt het zich tot de naaste sectorgenoten op basis van marktkapitalisatie:

Bedrijf Ticker Marktkapitalisatie K/W-verhouding
Avalon GloboCare Corp. ALBT $4.34M N/A
CBRE Group, Inc. CBRE $38.00B 29.6
KE Holdings Inc. BEKE $18.40B 37.5
Jones Lang LaSalle Incorporated JLL $13.43B 15.6

De gemiddelde K/W-verhouding in de Vastgoeddiensten-sector is 84.5x. Avalon GloboCare Corp. wordt verhandeld tegen een K/W van N/A.

Deze analyse is gegenereerd door AI en dient alleen ter informatie. Het vormt geen financieel advies. Gegevens kunnen vertraagd of onnauwkeurig zijn. Doe altijd je eigen onderzoek en raadpleeg een gekwalificeerde financieel adviseur voordat je beleggingsbeslissingen neemt.

Over Avalon GloboCare Corp.

Avalon GloboCare Corp., together with its subsidiaries, develops innovative artificial intelligence platforms in the United States and China. It operates through Consumer Health Technology and Artificial Intelligence Content Technology Segment. The company offers automated video generation, enterprise documentation, and workflow automation solutions, as well as cellular therapy and generative AI publishing and software. It also distributes the KetoAir device, which is a breathalyzer system that detects acetone levels in exhaled breath; and the AI Nutritionist software program that helps users monitor and manage ketogenic diet and related programs. Avalon GloboCare Corp. was founded in 2015 and is headquartered in Freehold, New Jersey.

Bedrijfsbeschrijving wordt in het Engels weergegeven.

Bezoek website →

Belangrijke Cijfers

Marktkapitalisatie
$4.34M
K/W-verhouding
N/A
52-weken hoog
$4.74
52-weken laag
$0.21
Gem. Volume
1.32M

Gegevens verstrekt door Yahoo Finance via yfinance. Dagelijks bijgewerkt.

Bedrijfsinfo

Beurs
NASDAQ
Land
United States
Werknemers
2